### Arkansas

**Estimated Number of Individuals Living with Hepatitis C:** 37,500

<table>
<thead>
<tr>
<th>Grade</th>
<th>Summary</th>
</tr>
</thead>
</table>
| F     | **Liver Damage (Fibrosis) Restrictions:** Arkansas requires severe liver damage (F3 or greater), depending on a patient's genotype and whether the individual is treatment naïve or experienced.  
**Sobriety Restrictions:** Arkansas requires abstinence from drugs and alcohol for at least six months.  
**Prescriber Restrictions:** Arkansas requires a specialist, or a provider working under direct supervision of a specialist, to prescribe.  
**Recommendations to Improve Patient Access:**  
- Remove liver damage, sobriety and prescriber requirements.  
- Maintain transparency regarding hepatitis C coverage requirements.  

*Grade Rationale: Arkansas imposes severely restrictive liver damage and sobriety requirements to access hepatitis C medications. With these restrictions, very few people with hepatitis C have access to treatment.*

### Background

As of March 2017, Arkansas had 912,043 individuals enrolled in Medicaid and Children's Health Insurance (CHIP). Arkansas Medicaid operates a Primary Care Case Management (PCCM) program in which the state contracts directly with primary care providers. The Medicaid program does not contract directly with any Managed Care Organizations (MCOs). However, in 2013, Arkansas opted to expand Medicaid with the General Assembly's passage of the Health Care Independence Act for adults with incomes up to 138 percent of the Federal Poverty Level (FPL). The state decided to use federal funding for those individuals to purchase private insurance through Arkansas' Health Insurance Marketplace (HIM). Individuals eligible for the Health Care Independence program have the entirety of their premium paid by the program. In 2017, Health Care Independence was renamed Arkansas Works. The state program determines hepatitis C coverage criteria for all enrollees.

### State of Medicaid Hepatitis C Treatment Access

Arkansas severely restricts access to hepatitis C medications. The state requires prior authorization (PA) and severe liver damage (F3 or greater) for patients to qualify for treatment. A beneficiary must be abstinent from alcohol or substance use for at least six months. If a patient is currently using substances, the PA form inquires if the individual is currently enrolled in a rehabilitation program. It is unclear if enrollment in a substance use program is a requirement to receive PA. The PA form also inquires if the patient is co-infected with HIV but does not impose any restrictions related to the individual's status. A course of therapy is limited to 12 to 16 weeks depending on the regimen prescribed. It is unclear if there are quantity limits or if PA can be extended to continue therapy if needed. The Preferred Drug List (PDL) includes the following preferred Direct-Acting Antiviral (DAA) regimens: Epclusa and Zepatier and non-preferred: Harvoni, Incivek, Olysio, Sovaldi, Technivie, Viekira Pak. The Medicaid program also limits the total number of medications a patient can be prescribed to three per month unless there is prior approval. This limit on the total number of medications a patient can be prescribed per month could pose an additional challenge to patients accessing treatment if the individual has other co-morbid conditions that need to be treated. Arkansas also requires a specialist or a physician working directly under the supervision of a hepatologist, gastroenterologist or infectious disease specialist to prescribe. A previous version of Arkansas' PA form (version: January 23, 2015) indicates the state's conservative approach to treatment. The PA states that the Medicaid program is monitoring the evolving therapeutic options for hepatitis C. Given the regular reporting of new results of several novel agents alone and in combination, the absence of long term clinical outcomes data, and the imminent approval of additional medications, Arkansas Medicaid has adopted a conservative approach to HCV therapy ... to be revised as new information becomes available. Many factors will be reviewed and prescribers may be asked to provide the medical necessity of urgency for treatment.

### Liver Damage (Fibrosis) Restrictions

Arkansas Medicaid requires severe liver damage (F3 or greater) depending on a patient's genotype and whether the individual is treatment naïve or experienced to access hepatitis C medication.
Sobriety Restrictions

Arkansas Medicaid requires abstinence from drugs and alcohol for at least six months. Additionally, if a beneficiary is a current substance user, the PA form inquires if the individual is enrolled in a rehabilitation program. The PA also states that the beneficiary's substance use history will be review prior to approval.

Prescriber Restrictions

The state requires a prescription to be written by a specialist: hepatologist, gastroenterologist, infectious disease or a prescriber working under the direct supervision of one of those specialty physicians.

Points of Contact for Questions & Concerns about Arkansas' State of Medicaid Hepatitis C Access

Medicaid Program: Dawn Stehle, Director, Division of Medical Services, Department of Human Services
Donaghey Plaza South, P.O. Box 1437, Slot S-401, Little Rock, AR 72203-1437;
Telephone: (501) 683-4997; Email Address: Dawn.Stehle@dhs.arkansas.gov

Drug Utilization Review (DUR) Board: Jason Derden, Pharmacy Administrator, Arkansas Medicaid Pharmacy Program, Division of Medical Services, Department of Human Services
Donaghey Plaza South, P.O. Box 1437, Slot S-415, Little Rock, AR 72203-1437;
Telephone: 501-683-4120; Email Address: Jason.Derden@dhs.arkansas.gov

---

1. HepVu, Arkansas State Profile: https://hepvu.org/state/arkansas/
3. Fact Sheet: Medicaid Managed Care Model Variations and Arkansas Applications, Ark. Ctr. for Health Improvement (September 2015): http://www.achi.net/docs/332
10. Ibid. Arkansas Medicaid Prescription Drug Program, Hepatitis C Virus (HCV) Medication Therapy Request Sheet
11. Ibid. Arkansas Medicaid Prescription Drug Program, Hepatitis C Virus (HCV) Medication Therapy Request Sheet
12. Ibid. Arkansas Medicaid Prescription Drug Program, Hepatitis C Virus (HCV) Medication Therapy Request Sheet
13. Ibid. Arkansas Medicaid Prescription Drug Program, Hepatitis C Virus (HCV) Medication Therapy Request Sheet
14. Ibid. Arkansas Medicaid Prescription Drug Program, Hepatitis C Virus (HCV) Medication Therapy Request Sheet
16. Arkansas Medicaid Program Overview SFY 2016; Division of Medical Services, Arkansas Department of Human Services: https://www.medicaid.state.ar.us/Download/general/M08SFY2016.pdf
18. Ibid. Arkansas Medicaid Prescription Drug Program, Hepatitis C Virus (HCV) Medication Therapy Request Sheet
19. Ibid. Arkansas Medicaid Prescription Drug Program, Hepatitis C Virus (HCV) Medication Therapy Request Sheet
20. Ibid. Arkansas Medicaid Prescription Drug Program, Hepatitis C Virus (HCV) Medication Therapy Request Sheet
21. Ibid. Arkansas Medicaid Prescription Drug Program, Hepatitis C Virus (HCV) Medication Therapy Request Sheet
23. Ibid. Arkansas Division of Medical Services Contacts, ARMedicaid